BioCentury
ARTICLE | Clinical News

Hana off on pipeline update

March 24, 2007 1:18 AM UTC

HNAB fell $1.31 (35%) to $2.41 on a newsy Friday that saw the company pull an NDA for one compound, suspend development of another and update its development plans for a third. HNAB is withdrawing an NDA for Zensana ondansetron to prevent chemotherapy, radiation and post-operative induced nausea and vomiting, following a review of a previously reported precipitation issue (See BioCentury Extra, Tuesday, Feb. 20, 2007).

The company said it plans to evaluate an alternative formulation of the oral spray with partner NovaDel (NVD) and hopes to resubmit the NDA next year. NVD was off $0.10 to $1.30. ...